**Core tip:** Calcium chelated N-acetylneuraminic acid-glycomacropeptide demonstrates effective anti-bactericidal activity against *Helicobacter pylori* both *in vitro* and *in vivo*.

INTRODUCTION
============

*Helicobacter pylori* (*H. pylori*) has been reported to be associated with many gastrointestinal diseases such as chronic gastritis, peptic ulcers, gastric carcinoma, and mucosa-associated lymphoid tissue lymphoma\[[@B1]-[@B3]\]. Until now, standard triple therapy consisting of a proton pump inhibitor and two broad-spectrum antibiotics, usually amoxicillin, clarithromycin or metronidazole, has been able to achieve eradication\[[@B3]-[@B5]\]. However, the Maastricht IV Consensus report recommended the careful choice of the antibiotic combination for treatment according to local *H. pylori* antibiotic resistance patterns due to multidrug resistance of *H. pylori*. For example, the concentrations of antibiotics for treatment of *H. pylori* infection were required at four times when *H. pylori* had local clarithromycin resistance\[[@B6]\]. Since antibiotic abuse had side effects and allowed development of resistance to antibiotics, alternative strategies have been proposed to counteract *H. pylori* infection. As an alternative approach, preservation of mucus from *H. pylori* attachment is emphasized because *H. pylori* infection disrupted the epithelial barrier which resulted in inflammation or cancer\[[@B7]\]. For example, dietary inhibitors such as lacto-oligosaccharide has been suggested as a solution for *H. pylori* infections\[[@B8]\]. Although oligosaccharides specific for the *H. pylori* lectins may potentially act as inhibitors of adhesion to mucus, their production in commercial amounts as anti-adhesion therapeutic agents is still a problem\[[@B9],[@B10]\]. Here, we introduce a new N-acetylneuraminic acid (NANA) combined glycomacropeptide (GMP) which was made from milk serum hydrolysis protein powder as an anti-*H. pylori* agent. Wadström et al\[[@B11]\] reported that NANA derivative had an adhesion potential to *H. pylori* lectins and Hirmo et al\[[@B12]\] reported that milk glycoprotein had an anti-*H. pylori* effect. We designed a new material with NANA, GMP, and calcium (CaG-NANA), and anti-*H. pylori* activities of CaG-NANA were investigated both *in vitro* and *in vivo*.

MATERIALS AND METHODS
=====================

H. pylori strain and experimental animals
-----------------------------------------

*H. pylori* strain (SS1-passed-5) was kindly provided by Helicobacter pylori Korean Type Culture Collection (HpKTCC, Jinju, South Korea) and grown in 1.5% agar added Brucella broth with 10% horse serum (No. CM0169; OXOID, Waltham, MA, United States). The pathogen-free (SPF) male ICR mice (20-22 g) were purchased from Orient Bio (Daejeon, South Korea). All the animals were housed in an SPF environment and had free access to sterile neutral water and standard mouse feed. The experimental procedures in this study were approved by the Experimental Animal Ethics Committee of Dankook University, South Korea (No. DKU14-036).

Supply of CaG-NANA
------------------

CaG-NANA and each component of CaG-NANA were provided by MediNutrol (Kwangju, South Korea). As shown in Figure [1A](#F1){ref-type="fig"}, CaG-NANA was manufactured from calcium (Ca), GMP, and NANA by chelating and enzyme methods where the component concentrations were 5%, 85%, and 7%, respectively. For comparing each produced compound, we wrote abbreviated form as standard NANA (S-NANA), GMP linked NANA (G-NANA), and calcium chelated G-NANA (CaG-NANA).

![Confirmation of N-acetylneuraminic acid. A: The scheme of CaG-NANA manufacture; B: HPLC analysis of NANA content in CaG-NANA. The condition of HPLC analysis is described in Table [1](#T1){ref-type="table"}. GMP: Glycomacropeptide; HPLC: High performance liquid chromatography; CaG-NANA: Calcium-glycomacropeptide-N-acetylneuraminic acid; S-NANA: Standard N-acetylneuraminic acid.](WJGP-7-300-g001){#F1}

High performance liquid chromatography for confirmation of NANA
---------------------------------------------------------------

###### 

High performance liquid chromatography analysis condition

  ------------------ -------------------------------------------------------------
  Detector           UV detector
  Wavelength         205 nm
  Column             Aminex HPX-87H Ion Exclusion column (300 mm × 7.8 mm, 9 μm)
  Mobile phase       10 mmol/L H~2~SO~4~ in water (isocratic)
  Running time       20 min
  Flow rate          0.5 mL/min
  Injection volume   10 mL
  Temperature        40 °C
  ------------------ -------------------------------------------------------------

For confirmation of NANA component, we analyzed CaG-NANA using high performance liquid chromatography (HPLC) method. HPLC analysis was performed using Agilent 1260 model equipped with a pump (G1311C), an auto sampler (G1329B), a column (G1316A), and a ultraviolet detector (G1314F), which was purchased from Agilent (Santa Clara, CA, United States). The condition of analysis was described in Table [1](#T1){ref-type="table"}.

Culture and collection of H. pylori
-----------------------------------

*H. pylori* was incubated in Brucella medium contained the selective supplements (No. SR0083; OXOID, Waltham, MA, United States) under microaerobic environment (15% CO~2~, 5% O~2~, 80% N~2~) at 37 °C for 72 h. The bacterial colonies were collected and identified with a Pronto-Dry infection kit (Kokab Enterprise, Karachi, Pakistan) for bactericidal tests *in vitro*.

Inhibitory effect of CaG-NANA on H. pylori in vitro
---------------------------------------------------

The inhibitory activity of CaG-NANA against the growth of *H. pylori* was assessed using an agar dilution method. Briefly, 0.1%, 0.25%, or 0.5% of CaG-NANA and its components were added to the Brucella agar. The non-drug agar served as a negative control. Agar plates were inoculated with *H. pylori* at serial concentrations of 1 × 10^8^, 1 × 10^7^, and 1 × 10^6^ colony forming units (CFU)/mL and cultured for 72 h. The minimal inhibitory concentration (MIC) was defined as the minimal concentration of CaG-NANA required for complete inhibition of *H. pylori* growth. The colonies were counted using image J (https://imagej.nih.gov/ij/) after 72 h incubation and the average number was calculated. Bactericidal activity was evaluated using time-kill curves with 0.5, 1.0 and 2.0 × MIC of CaG-NANA compared with the blank controls.

Experimental design in vivo
---------------------------

Mice (*n* = 40) were randomly divided into four groups: Blank control, *H. pylori* infected control, antibiotic treatment, and CaG-NANA treatment. *H. pylori* (1 × 10^9^ /mL) was administered by gastric intubation to mice three times in a week except the blank control, and *H. pylori* infection was detected with gastric irrigation from randomly selected mice using an *H. pylori* detection test kit which was purchased from Pronto Dry (Brignais, France; Supple 1A). The antibiotic treatment was performed with a suspension of amoxicillin (12.33 mg/kg), metronidazole (164.40 mg/kg), and clarithromycin (205.54 mg/kg) which were equivalent to clinical administration (Dankook University hospital, Korea). Treatments with CaG-NANA and each component including NANA, S-NANA, and G-NANA were performed by oral administration every day for 3 wk, and the experimental design is shown in Figure [2A](#F2){ref-type="fig"}.

![Inhibitory effect of calcium-glycomacropeptide-N-acetylneuraminic acid on *Helicobacter pylori in vitro*. Agar plates were inoculated with *Helicobacter pylori* (*H. pylori*) at serial concentrations of 1 × 10^8^, 1 × 10^7^, and 1 × 10^6^ CFU/mL and cultured for 72 h. The minimal inhibitory concentration (MIC) was defined as the minimal concentration of materials required for complete inhibition of *H. pylori* growth. Bactericidal activity was evaluated using time-kill curves with 0.5, 1.0 and 2.0 × MIC of CaG-NANA compared with blank controls. All experiments were performed three times and significance was set at ^a^*P* \< 0.1 and ^b^*P* \< 0.05. A: Picture of colony forming unit assay; B: GMP; C: CaG; D: S-NANA; E: G-NANA; F: CaG-NANA. GMP: Glycomacropeptide; CaG: Calcium-glycomacropeptide; S-NANA: Ststandard N-acetylneuraminic acid; CaG-NANA: Calcium-glycomacropeptide-N-acetylneuraminic acid.](WJGP-7-300-g002){#F2}

Histological observation
------------------------

The animals were deprived of feed but allowed free access to water for 24 h before sacrificed. At the end of sacrifice, blood was collected from mouse and gastric tissues were removed and fixed in 10% formalin. After fixation, tissues were processed and embedded in paraffin. The paraffin blocks were cut into 4 μm sections and stained with Harris' hematoxylin and eosin for histological observation under a microscope (BX51, Olympus, Miami, FL, United States).

Enzyme-linked immunosorbent assay
---------------------------------

The expression levels of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and IL-10 in blood serum were determined using enzyme-linked immunosorbent assay (ELISA). Mouse ELISA kits were purchased from R&D Systems (Minneapolis, MN, United States). The assays were performed according to the manufacturer's instructions and repeated in triplicate.

Statistical analysis
--------------------

Eradication rates were compared among groups by one-way analysis of variance (Kruskal-Wallis) and Dunn's multiple comparison test (GraphPad Software Inc., La Jolla, CA, United States). *P* \< 0.05 was considered statistically significant.

RESULTS
=======

Confirmation of NANA
--------------------

As shown Figure [1B](#F1){ref-type="fig"}, the NANA component of CaG-NANA showed the same purity as standard NANA.

Inhibitory effect of CaG-NANA on H. pylori in vitro
---------------------------------------------------

The bactericidal effects of CaG-NANA and each component against *H. pylori* were assessed *in vitro*. We described previously that CaG-NANA is composed of NANA, GMP and calcium, thus we tested the anti-bacterial effects of every component used in CaG-NANA synthesis. As shown in Figure [1](#F1){ref-type="fig"}, S-NANA, G-NANA and CaG-NANA had an anti-bacterial effect (Figure [1D](#F1){ref-type="fig"}, E and F) whereas GMP and GMP with calcium (CaG) had no activity in the colony forming assay (Figure [1B](#F1){ref-type="fig"} and C).

This result indicated that only NANA included compound had anti-bacterial activity.

Inhibitory effect of CaG-NANA on H. pylori in vivo
--------------------------------------------------

For the *in vivo* study, we divided mice into four groups and 1 × 10^9^/mL CFU of *H. pylori* was administered into mice three times for one week except the negative group. *H. pylori* infection was confirmed by gastric irrigation using an *H. pylori* detection test kit (Pronto Dry). After confirmation, treatments with antibiotics, CaG-NANA and its components were orally administered every day for 3 wk. The doses of antibiotics were described in the "Material and Methods" section (Figure [3A](#F3){ref-type="fig"}). The doses of CaG-NANA and its components were fixed at 0.5% (v/w). We followed the mouse weight after treatment. As shown in Figure [3B](#F3){ref-type="fig"}, mouse weight was decreased in the S-NANA and *H. pylori* positive control groups. From this result, S-NANA was considered to have toxicity at 0.5% of concentration.

![Inhibitory effect of calcium-glycomacropeptide-N-acetylneuraminic acid on *Helicobacter pylori in vivo*. Antibiotic doses are described in the "materials and methods" section. A: Schematic design of *in vivo* study; B: Weight changes of mice. HP: Helicobacter pyroli; S-NANA: Standard N-acetylneuraminic acid; G-NANA: Glycomacropeptide-N-acetylneuraminic acid; CaG-NANA: Calcium-glycomacropeptide-N-acetylneuraminic acid.](WJGP-7-300-g003){#F3}

Next, we observed the gastric mucus layer of mice. The majority of the *H. pylori* population reside in the mucus which binds the organisms *via* specific interactions such as pathogen adherence. Normal gastric mucosa has a uniform surface epithelium (Figure [4A](#F4){ref-type="fig"}), whereas *H. pylori* infected gastric mucosa has an irregular outline of the epithelium layer along with neutrophil and macrophage infiltrations (Figure [4B](#F4){ref-type="fig"}). In addition, bacterial attachment is mediated by outer membrane adhesions that bind to glycoconjugates present in the gastric mucus layer, lining the surface epithelium of the gastric mucosa in the *H. pylori* infected group. As shown in Figure [4C](#F4){ref-type="fig"}, the antibiotic treatment group had decreased infiltration of macrophages and adhesion of *H. pylori* colonization, however, the destruction of surface epithelium layers was also observed. Meanwhile, every NANA including group showed uniformed surface epithelium layers. Interestingly, many macrophages and neutrophils were observed in the S-NANA treatment group (Figure [4D](#F4){ref-type="fig"}). The damage to surface epithelium in the antibiotics treatment group and inflammation observed in the S-NANA treatment group might be related to mouse weight loses. Both the G-NANA and CaG-NANA treatment groups showed the detachment of *H. pylori* colonization without any damage to surface epithelium or inflammation (Figure [4E](#F4){ref-type="fig"} and F).

![Histology of the gastric mucosa. Mouse stomachs were removed and underwent hematoxylin and eosin staining. *H. pylori* colonization and macrophage infiltration were observed under a light microscope. A: Normal group; B: *H. pylori* infected group; C: Antibiotics treated group; D: S-NANA treated group; E: G-NANA treated group; F: CaG-NANA treated group. S-NANA: Standard N-acetylneuraminic acid; G-NANA: Glycomacropeptide-N-acetylneuraminic acid; CaG-NANA: Calcium-glycomacropeptide-N-acetylneuraminic acid.](WJGP-7-300-g004){#F4}

We also assessed the levels of IL-1β, IL-6, TNF-α, and IL-10 in blood by ELISA. PBS was used as a control because every compound was dissolved in PBS. Both of S-NANA and CaG-NANA showed a potent ability to decrease inflammatory cytokines. The level of IL-1β was reduced from 7.6 ng/mL to 0.8 ng/mL after S-NANA treatment and 2.36 ng/mL after CaG-NANA treatment (Figure [5A](#F5){ref-type="fig"}). The level of IL-6 was remarkedly decreased from 113.4 ng/mL to 33.5 ng/mL after S-NANA treatment and 1.26 ng/mL after CaG-NANA treatment (Figure [5B](#F5){ref-type="fig"}). The level of TNF-α was also reduced to 8.21 ng/mL after S-NANA treatment and 1.44 ng/mL after CaG-NANA treatment (Figure [5C](#F5){ref-type="fig"}). Meanwhile, the level of IL-10 was reduced only in the CaG-NANA treatment group from 7.62 ng/mL to 6.3 ng/mL (Figure [5D](#F5){ref-type="fig"}).

![Expression levels of interleukine-1β, interleukine-6, tumor necrosis factor-α, and interleukine-10 in blood serum determined by enzyme-linked immunosorbent assay. The assays were performed according to the manufacturer's instructions and all experiments were repeated in triplicate. Statistical analysis was performed using Dunn's multiple comparison test with significance set at ^a^*P* \< 0.1 and ^b^*P* \< 0.05, ^c^*P* \< 0.01. A: IL-1β; B: IL-6; C: TNF-α; D: IL-10. IL: Interleukine; TNF: Tumor necrosis factor; S-NANA: Standard N-acetylneuraminic acid; G-NANA: Glycomacropeptide-N-acetylneuraminic acid; CaG-NANA: Calcium-glycomacropeptide-N-acetylneuraminic acid.](WJGP-7-300-g005){#F5}

DISCUSSION
==========

The anti-*H. pylori* effects of antibiotic formulas have been investigated, but the findings are limited by varying drug quality and sources, as well as the numerous and complicated components of formulas. Thus, it has been suggested that dietary inhibitors may be a solution for certain infections as an alternative approach\[[@B8]\]. Eradication of *H. pylori* has remained difficult for reasons that lie in the biology and environment of the organism. *H. pylori* populations colonize epithelial cells that line the antrum of the stomach and survive in the acidic environment\[[@B13]\]. Most anti-microbial agents are poorly secreted in the gastric mucosa because of the stomach environment\[[@B14]\], and the residues expressed on *H. pylori* enable specific binding to the mucus layers. Thus, CaG-NANA was excogitated to overcome the acidic environment of the stomach and have bactericidal activity by interrupting glycol-conjugation of *H. pylori* on the mucosa.

CaG-NANA, a compound of N-acetylneuraminic acid with calcium combined glycomacropeptide, demonstrated an anti-bacterial effect against *H. pylori*. We manufactured CaG-NANA as a dietary inhibitor against *H. pylori*; NANA was demonstrated as an *H. pylori* adhesion blocker\[[@B9],[@B15],[@B16]\], glycomacropeptide was used for modulating the acidic phase of the stomach, and calcium was inserted for improvement as functional food. NANA content in CaG-NANA was evaluated compared to S-NANA by HPLC, which confirmed its content and purity (Figure [1B](#F1){ref-type="fig"}). CaG-NANA at concentrations \> 0.25% regulated the population of *H. pylori in vitro*. S-NANA also decreased the population of *H. pylori in vitro* (Figure [2D](#F2){ref-type="fig"}); however, S-NANA resulted in a severe weight loss *in vivo* (Figure [3B](#F3){ref-type="fig"}), which demonstrated that S-NANA treatment only had negative utility. Meanwhile, G-NANA and CaG-NANA had bactericidal and anti-adhesion effects on glyco-conjugation of the mucosa without toxicity. Bacterial attachment is mediated by outer membrane adhesions that bind to glycoconjugates present in the gastric mucus layer and lining the surface epithelium of the gastric mucosa\[[@B17]\].

*H. pylori* is also known to induce inflammatory response that includes the up-regulation of pro-inflammatory cytokines. CaG-NANA exerted a down-regulatory effect on pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and IL-10. Reduction of pro-inflammatory cytokines induced by *H. pylori* is responsible for the recruitment of macrophages and neutrophils in the lamina propria. CaG-NANA exerted an antagonistic effect against *H. pylori*, which is an anti-microbial effect *via* different mechanisms from those of antibiotics.

This study suggests that it is possible to decrease the number of *H. pylori* or its activation in the stomach through a regular ingestion of N-acetylneuraminic acid containing glycomacropeptide as dietary products. Moreover, CaG-NANA is a complex compound which can be manufactured in large scale at a low cost under good manufacturing practice (GMP). In conclusion, the anti-*H. pylori* effects of CaG-NANA were confirmed both *in vitro* and *in vivo*, which provided experimental support for future human trials.
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